WS
AKTX

Wedbush Securities’s Akari Therapeutics AKTX Stock Holding History

Wedbush Securities’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-39
Closed -$55K – 870
2020
Q3 		$55K Buy
+39
New +$57.8K 0.01% 872

Other funds holding AKTX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
OFW
Omnia Family Wealth Aventura, Florida $373M AUM 25.3% 1-Year Est. Return
UAS
United Asset Strategies Garden City, New York $1.41B AUM 27.73% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wedbush Securities's AKTX Position: Q4 2020 in Review

Wedbush Securities sold out of Akari Therapeutics (AKTX) in Q4 2020, closing a stake of 39 shares — an estimated $55K sold.

Wedbush Securities first reported a position in AKTX in Q3 2020 and held it in 1 quarter. The position peaked at $55K in Q3 2020. 12 funds tracked by Wall St. Rank hold AKTX as of Q4 2020.

  • Wedbush Securities reported no remaining Akari Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Wedbush Securities sold 39 Akari Therapeutics shares in Q4 2020, an estimated $55K.
  • Wedbush Securities first reported a position in Akari Therapeutics in Q3 2020 and held it in 1 quarter.
  • Wedbush Securities's Akari Therapeutics position peaked at $55K in Q3 2020.
  • 12 funds tracked by Wall St. Rank held Akari Therapeutics as of Q4 2020.

Based on Wedbush Securities's 13F filing for Q4 2020, filed 16 Feb 2021.